Group One for Coronary Artery Disease

Phase-Based Progress Estimates
Coronary Artery Disease+1 More
Sugammadex - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing if Sugammadex will help reduce time from anesthesia reversal to extubation, and improve other post-extubation outcomes, in patients who have had coronary artery bypass surgery.

Eligible Conditions
  • Coronary Artery Disease
  • Surgery

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: 30-60 minutes post-extubation

Day 100
Length of Stay cardiac intensive care unit
Hour 24
Occurrence of Postoperative Respiratory Complications
2 hours post-extubation
Post-extubation Oxygen Requirements
Hour 2
Oxygen Saturation
24 hours post-extubation
Reintubation Incidence
30-60 minutes post-extubation
Peak Flow Rate
Swallowing Capacity
Hour 2
Blood Pressure
Heart rate
Day 3
Time to Extubation
Hour 1
Tidal Volume
Hour 2
Occurrence of Postoperative Cardiac Complications

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Group One
1 of 2
Group Two
1 of 2

Active Control

84 Total Participants · 2 Treatment Groups

Primary Treatment: Group One · No Placebo Group · Phase 4

Group OneActiveComparator Group · 3 Interventions: Rocuronium, Neostigmine, Glycopyrrolate · Intervention Types: Drug, Drug, Drug
Group TwoActiveComparator Group · 2 Interventions: Sugammadex, Rocuronium · Intervention Types: Drug, Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 30-60 minutes post-extubation

Who is running the clinical trial?

West Virginia UniversityLead Sponsor
156 Previous Clinical Trials
49,865 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Isolated coronary artery bypass graft surgery.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 19th, 2021

Last Reviewed: November 19th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.